$0
Obe-cel’s BLA Submission on Track for YE 2023; Launch Preparedness Activities Underway; Cardinal Health to Serve as Autolus’s US Commercial Distribution Partner; Autolus’s Q1 2023 Earnings Call Summary
Autolus has had a series of updates recently, including a Capital Markets Day, an earnings call, and other related news items. On Thursday, May 4, Autolus held its Q1 2023 earnings call (press release / presentation) highlighting that obe-cel’s BLA submission to the FDA remains on track for YE 2023. Below, Celltelligence provides summary and insight on the recent updates from Autolus, including obe-cel’s launch approach and the company’s US distribution agreement with Cardinal Health.